Results 51 to 60 of about 8,807 (99)

Two Cases of Exacerbation of Asthma during Treatment with Enfortumab Vedotin

Case Reports in Oncology, 2023
Enfortumab vedotin is an antibody-drug conjugate against nectin-4 that is recently being used in the management of patients with urothelial carcinoma. The common adverse events include rashes, peripheral neuropathy, and hyperglycemia. Only a few cases of
Takamasa Homma, Kuniaki Tanaka, Naoya Takeda, Yu Okada, Shota Torii, Hideki Esaki, Takashi Sakakibara, Norio Takimoto   +7 more
doaj   +1 more source

Managing Skin Side Effects Associated With Oncology Treatments: Asian Perspective on Use of Dermocosmetics

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Skin adverse events (AEs) frequently accompany all types of anticancer treatments. This publication discusses how recent international guidance on best‐practices use of dermocosmetics can be adapted to the North Asia region (China, Hong Kong, Japan, Republic of Korea, and Taiwan).
Meng Pan, Jianguo Sun, Makoto Kawashima, You Chan Kim, Mison Chun, Chia‐Yu Chu, Yi‐Hsin Liang, Mee Chang, Delphine Kerob, Brigitte Dreno   +9 more
wiley   +1 more source

Optimizing Body Size‐Based Dosing Approaches for Antibody–Drug Conjugates

Clinical Pharmacology &Therapeutics, Volume 119, Issue 4, Page 872-880, April 2026.
Optimized dosing precision of antibody–drug conjugates (ADCs) remains challenging due to narrow therapeutic indices, efficacious doses near the maximum tolerated dose, and substantial interindividual variability in exposure. Body size‐based dosing can reduce exposure variability when the allometric scaling exponent for clearance α = 1 but may over‐ or ...
Andrew B. SyBing, Diane D. Wang
wiley   +1 more source

Crohn's lymphoid aggregates with endothelial clusters colocalise with submucosal fibrosis in fibrostenosing Crohn's disease

The Journal of Pathology, Volume 268, Issue 4, Page 398-412, April 2026.
Abstract Crohn's disease (CD) involves chronic transmural inflammation of the intestines, leading to progressive wall fibrosis with stenosis and luminal obstruction, predominantly in the terminal ileum. Fibrosis is a significant therapeutic challenge, thus improved understanding of localisation, cellular composition, and cell–cell interactions in CD ...
Michael Glinka, Gregory J Wickham, Francesca Nadalin, Kathryn J Kirkwood, Helen Caldwell, Mike Wicks, Bill Hill, Derek Houghton, Mehran Sharghi, Amirhosein Kefayat, Bernard Haggarty, Albert Burger, Richard A Baldock, David J Adams, Irene Papatheodorou, Peter Bankhead, Shahida Din, Mark J Arends   +17 more
wiley   +1 more source

Enfortumab vedotin plus pembrolizumab in treatment‐naïve metastatic urothelial carcinoma patients: An Austrian real‐world analysis

International Journal of Cancer, Volume 158, Issue 6, Page 1654-1665, 15 March 2026.
What's new? New antibody‐drug conjugates (ADCs) and immunotherapies have helped expand treatment options for urothelial carcinoma (UC). Clinical trials suggest that the ADC enfortumab vedotin (EV) and the immunotherapeutic agent pembrolizumab, when used in combination, are especially effective against UC.
Dora Niedersuess‐Beke, Karl Mayrhofer, Johanna Krauter, Johannes Franke, Dominic Vais, Maximillian Pallauf, David Kiesl, Ferdinand Luger, Jacob Pfuner, Angelika Terbuch, Thomas Bauernhofer, Jasmin Spielgelberg, Andreas Banner, Stefan Aufderklamm, Clemens Wiesinger, Susanne Schnabel, Simon Peter Gampenrieder, Josef Mühlmann, Sonia Vallet, Sabine Weibrecht, Franz Stoiber, Haleh Andalibi, Harun Fajkovic, Hossein Taghizadeh, Jan Miechowiecki, Roman Taedcke, Daniel Heintel, Shahrokh F. Shariat, Martin Pichler, Wolfgang Hilbe, Renate Pichler   +30 more
wiley   +1 more source

Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker

Molecular Oncology, Volume 20, Issue 3, Page 823-837, March 2026.
Urinary LGALS3BP is elevated in bladder cancer patients compared to healthy controls as detected by the 1959 antibody–based ELISA. The antibody shows enhanced reactivity to the high‐mannose glycosylated variant secreted by cancer cells treated with kifunensine (KIF).
Asia Pece, Giulio Lovato, Ilaria Cela, Arianna Mercatelli, Benedetta Ferro, Jussi Nikkola, Sara Pagotto, Tommaso Grottola, Vincenzo De Laurenzi, Rossella Cicchetti, Antonio Marchetti, Luigi Schips, Rossano Lattanzio, Stefano Iacobelli, Emily Capone, Peter Black, Mads Daugaard, Michele Marchioni, Gianluca Sala   +18 more
wiley   +1 more source

Spatial heterogeneity of antibody–drug conjugate targets in pancreatic ductal adenocarcinoma

The Journal of Pathology: Clinical Research, Volume 12, Issue 2, March 2026.
Abstract Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease, with limited therapeutic options, few patients showing targetable molecular changes. New therapeutic strategies are necessary. Antibody–drug conjugates (ADCs) have emerged as alternative therapeutic strategies across various cancer types. Herein, we analyze the expression and spatial
Deema Sabtan, Marie‐Lisa Eich, Florian Loch, Julen Karl Pérez Zuschneid, Markus Möbs, Judith Böhme, Frederick Klauschen, David Horst, Mihnea P Dragomir, Gabriel Dernbach, Simon Schallenberg   +10 more
wiley   +1 more source

Host nectin-1 is required for efficient Chlamydia trachomatis serovar E development.

Frontiers in Cellular and Infection Microbiology, 2014
Interaction of Herpes Simplex Virus (HSV) glycoprotein D (gD) with the host cell surface during Chlamydia trachomatis/HSV co-infection stimulates chlamydiae to become persistent.
Jennifer Vanover Hall, Jennifer Vanover Hall, Jingru eSun, Jessica eSlade, Jessica eSlade, Jennifer eKintner, Marissa eBambino, Judy eWhittimore, Robert V. Schoborg, Robert V. Schoborg   +9 more
doaj   +1 more source

Decoding the Cellular Heterogeneity and Malignant Progression of Human Penile Squamous Cell Carcinoma by Single‐Cell RNA Sequencing

Advanced Science, Volume 13, Issue 14, 9 March 2026.
Single‐cell transcriptomic and functional analyses identify SEMA3C as a key regulator of tumor progression and tumor microenvironment remodeling in penile squamous cell carcinoma. SEMA3C promotes epithelial–mesenchymal transition, tumor growth, and invasion while shaping an immunosuppressive microenvironment, highlighting its potential as a prognostic ...
Xiheng Hu, Wensheng Shi, Liang Dong, Lingjuan Huang, Xiyuan Zhang, Yiting Feng, Jie Sun, Lanlan Liu, Teng Liu, Jun Fu, Bowen Zhong, Qihao Leng, Xiaohua Wu, Minfeng Chen, Lingfang Li, Yuan Li, Xin Jin, Long Wang, Jian Cao, Xin Li, Mingzhu Yin, Xiang Chen   +21 more
wiley   +1 more source

Cytokine‐Engineered Chimeric Antigen Receptor‐T Cell Therapy: How to Balance the Efficacy and Toxicity

Advanced Science, Volume 13, Issue 14, 9 March 2026.
Cytokine‐engineered CAR‐T cells represent a promising immunotherapy against malignancies due to direct tumor killing and potent immunity response. However, significant toxicities, including CRS and ICANS, have restricted clinical applications. How to keep the risk‐benefit balance of the advanced therapy is of great importance for maximizing the benefit
Xinru Zhang, Gulizeba Aimaiti, Yuanye Guan, Yuzhe Sha, Wei Zhou, Jiefeng Shen, Bo Zhao, Wei‐En Yuan   +7 more
wiley   +1 more source